Search research articles
Contact Us
Filters
Showing results (61-70 of 95) with videos related to
Page
of 10
Sort By:
The Lancet. Haematology
|
September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Blood Cancer Journal
|
June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
Shaji Kumar, Lawrence Baizer, Natalie S Callander, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society
|
January 14, 2022
Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis
Moazzam Shahzad, Sibgha Gull Chaudhary, Muhammad U Zafar, et al.
Ophthalmology and Therapy
|
July 27, 2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Ophthalmology and Therapy
|
September 13, 2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Leukemia & Lymphoma
|
September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
Muhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
British Journal of Haematology
|
August 19, 2011
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
Julie E Chang, Christopher Peterson, Sangbum Choi, et al.
Transplantation and Cellular Therapy
|
July 20, 2021
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Moazzam Shahzad, Raheel S Siddiqui, Iqra Anwar, et al.
Cancer
|
April 17, 2024
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, et al.
Blood Cancer Journal
|
May 27, 2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
Sagar Lonial, Ajay K Nooka, Praneetha Thulasi, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 95) with videos related to
Sort By:
Page
of 10
The Lancet. Haematology
|
September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Blood Cancer Journal
|
June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
Shaji Kumar, Lawrence Baizer, Natalie S Callander, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society
|
January 14, 2022
Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis
Moazzam Shahzad, Sibgha Gull Chaudhary, Muhammad U Zafar, et al.
Ophthalmology and Therapy
|
July 27, 2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Ophthalmology and Therapy
|
September 13, 2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Leukemia & Lymphoma
|
September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
Muhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
British Journal of Haematology
|
August 19, 2011
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
Julie E Chang, Christopher Peterson, Sangbum Choi, et al.
Transplantation and Cellular Therapy
|
July 20, 2021
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Moazzam Shahzad, Raheel S Siddiqui, Iqra Anwar, et al.
Cancer
|
April 17, 2024
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, et al.
Blood Cancer Journal
|
May 27, 2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
Sagar Lonial, Ajay K Nooka, Praneetha Thulasi, et al.
Page
of 10